Developer docs
API playgroundTry for free, no card

Search company profiles

VectorBuilder

Full company profile

uuid00006zn

Namestring
VectorBuilder
Legal namestring
VectorBuilder Inc.
Company typeenum
Private
Founded yearint
2014
Descriptiontext

VectorBuilder is a privately held gene-delivery contract research, development, and manufacturing organization (CRO/CDMO) that operates an integrated online platform and physical manufacturing footprint to serve academic researchers, biotech, and pharmaceutical customers from research through GMP clinical manufacturing. The company's core technology is the Vector Design Studio — a self-serve web platform used in over 300,000 laboratories globally — paired with the free VectorBee DNA design software, an extensive catalog of backbones and components, and instant quote/pricing functionality. Revenue is generated through five streams: fee-for-service custom gene delivery (cloning, virus packaging, plasmid preparation, library construction, stable cell line engineering, recombinant protein expression), product sales (premade viruses, AAV serotype testing panels, LentiBuilder packaging kits, popular vectors), full-service CDMO/GMP manufacturing (plasmid, viral vector, IVT RNA, LNP, and engineered cell products) plus the CliniVec clinical consultation service, a store-credit program offering up to 20% bonus credit for pre-payment, and licensing/royalty arrangements (inbound from TET Systems and Demeetra/PiggyBac, plus outbound from proprietary platforms such as MiniVec, MuteFree AAV, MegaAAV, and novel AAV capsids). Go-to-market combines product-led growth through the self-serve online store, inside sales via territory managers, enterprise field sales for CDMO and CliniVec engagements, and a multi-region distributor network across Europe, the Middle East, and Asia Pacific.

The company is structured around US parent VectorBuilder Inc. (headquartered in Chicago, Illinois), core operating entity VectorBuilder Biotechnology in Guangzhou, China, regional entities in Germany (VectorBuilder GmbH) and the United Kingdom (VectorBuilder Ltd.), and local presences in Japan and Korea. In October 2022 VectorBuilder Biotechnology closed a CNY 410 million Series C funding round co-led by Legend Capital and Suikai Investment (with Guangzhou Yuexiu Industrial Investment Fund, Guangzhou Industrial Investment Group, Wanlian Tianze, and Xiamen C&D) to fund technology upgrades, capacity expansion, and global business development. Subsequent strategic actions include a $50M Chicago Advanced Biomanufacturing and R&D Center (announced May 2026, operations expected 2027), an EU patent for the proprietary MiniVec plasmid system (May 2026), the launch of the MuteFree AAV backbone (April 2026), a strategic partnership with MaxCyte for ex vivo cell engineering (June 2026), and a collaboration with Ikarovec on the ophthalmology gene therapy IKAR-003 (January 2026, potential $1B+ deal value). The company won the BioIndustrial Innovation of the Year award in 2024 and is recognized as a key player in the viral capsid development market alongside PackGene Biotech, Sartorius AG, and Revvity.

Short descriptiontext

VectorBuilder is a privately held gene-delivery CRO and CDMO operating an integrated online design platform (Vector Design Studio, used in 300,000+ labs) and global manufacturing footprint spanning research-grade cloning and virus packaging through GMP plasmid, viral vector, IVT RNA, LNP, and engineered cell production for academic, biotech, and pharmaceutical customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersChicago, United States
HQ citystring
Chicago
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
custom vector cloning, virus packaging services, CDMO gene therapy, GMP plasmid manufacturing, AAV lentivirus production
Industry5 codes
PRIMARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAB
Lentiviral Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAKAD
Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
Product category
Gene Delivery CDMO and Custom Vector Services
GTM motion6 records

Each record includes

Type, Description, Source

Revenue model5 records
1Custom Gene Delivery Services (Fee-for-Service)
TypeProfessional Services
Description

Contract manufacturing / fee-for-service revenue for custom vector cloning, virus packaging, plasmid preparation, library construction, stable cell line engineering, and recombinant protein expression. Default payment terms Net30.

en.vectorbuilder.com
2Product Sales (Premade Vectors, Viruses, Kits)
TypeOne Time License
Description

Catalog sales of premade viruses, AAV serotype testing panels, LentiBuilder packaging kits, popular vectors, and consumables ordered directly through the online store.

en.vectorbuilder.com
3CDMO / GMP Manufacturing
TypeManaged Services
Description

Full-service CDMO providing GMP-grade plasmid manufacturing, viral vector manufacturing, IVT RNA and LNP manufacturing, plus CliniVec therapeutic consultation services to clinical-stage cell and gene therapy developers.

en.vectorbuilder.com
4Store Credit & Promotional Pre-Paid Credits
TypeSubscription Recurring
Description

Non-refundable store credit program offering up to 20% bonus credit for future purchases, providing cash-flow positive pre-payment and lock-in.

en.vectorbuilder.com
5Licensing & Royalty Arrangements
TypeLicensing Royalties
Description

Licensing revenue from outbound licenses (PiggyBac from Demeetra, Tet3G from TET Systems) and inbound IP licensing arrangements for proprietary vector systems such as MiniVec, MuteFree AAV, novel AAV capsids, codon-optimized gene sequences, and proprietary virus packaging plasmids.

en.vectorbuilder.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Infrastructure, Technology or R&D, Marketing or Sales, Operations, Supply Chain
Pricing details5 tiers
1Custom quote-based pricing for vector cloning, virus packaging, and CDMO services
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Pricing calculated automatically on the online Vector Design Studio, or via Get Quote / Purchase Now with credit card. Price Match Program available for identical products from recognized competitors.

en.vectorbuilder.com
2Free first vector promotion (up to $500 off)
ModelFreemiumBilling cadencePay-as-you-go
Notes

Limited-time offer for first-time direct-buy customers on the English website using code FREEVECTOR-397; vector ID cannot start with VB01 or VB90; campaign Jun 1–Jun 29, 2026. Not valid in China, Japan, and South Korea markets.

en.vectorbuilder.com
312th Anniversary Welcome Offer (20% / 15% / 10% off tiers)
ModelOtherBilling cadencePay-as-you-go
Notes

Up to $1,000 off per order. 1st order 20% off (code Thankyou1st), 2nd order 15% off, 3rd order 10% off. Campaign June 10 – Sept 10, 2026. New accounts must register with organizational email.

en.vectorbuilder.com
4Referral Program (20%-off for new referee, 30%-off reward for referrer)
ModelOtherBilling cadencePay-as-you-go
Notes

Up to $1,000 off per order. Referee code must use institutional email. Limited to end users only; max 2 individuals per lab.

en.vectorbuilder.com
5Store Credit purchase (up to 20% bonus)
ModelSubscriptionBilling cadencePay-as-you-go
Notes

Non-refundable store credit can be purchased and used on any VectorBuilder product or service; does not expire.

en.vectorbuilder.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 7 records shown
1VectorBee
Description

Free DNA editing and design software offered as a companion to the VectorBuilder platform (vectorbee.com).

en.vectorbuilder.com
+6 more records
Core offering1 text field

VectorBuilder is an online platform and contract manufacturer that designs, engineers, and produces custom gene delivery tools including vectors, viruses, plasmids, recombinant proteins, stable cell lines, and GMP-grade cell-and-gene-therapy materials. Its integrated Vector Design Studio lets researchers design and order custom vectors online, while its CDMO arm delivers GMP plasmid, viral vector, IVT RNA, LNP, and engineered cell manufacturing supported by proprietary platforms such as MiniVec, MuteFree AAV, MegaAAV, and LentiBuilder.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Online Vector Design (Vector Design Studio)
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-06-23
Description

Strategic partnership to co-develop a next-generation gene delivery solution combining VectorBuilder's MiniVec plasmid system with MaxCyte's Flow Electroporation technology for ex vivo cell engineering applications. Preliminary CAR-T manufacturing data demonstrated 2.4x increased cell viability and 1.4x higher gene expression compared to conventional systems, addressing critical challenges in safety and manufacturability for cell therapies.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-06
Description

Collaborating on an eye disease gene therapy, IKAR-003, designed to be delivered in a doctor's office. The partnership is still in early stages but could be valued at over $1 billion once finalized.

Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Authorized distributor covering Germany, Switzerland, and Austria markets, listed on the VectorBuilder distributors page.

Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Authorized distributor for the Italian market, listed on the VectorBuilder distributors page.

Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Authorized distributor covering the Hungarian market, listed on the VectorBuilder distributors page.

Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Authorized distributor covering the Israeli market, listed on the VectorBuilder distributors page.

7Sci-Hub (sci-hub.com)
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Authorized distributor covering Malaysia, Singapore, and Indonesia, listed on the VectorBuilder distributors page.

en.vectorbuilder.com
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Authorized distributor covering the Korean market, listed on the VectorBuilder distributors page; VectorBuilder also maintains its own Korean-language website (vectorbuilder.kr) with additional distributors.

9TET Systems
Strategic tierMinorTypeOEM/ Whitelabel/ Licensing Partner
Description

Licensor of the patented Tet3G sequence component used in VectorBuilder's Tet-inducible vector products. VectorBuilder holds an inbound license and grants automatic research-use licenses to academic institutions with purchase; commercial users require a separate TET Systems license.

en.vectorbuilder.com
Strategic tierMinorTypeOEM/ Whitelabel/ Licensing Partner
Description

PiggyBac® is a licensed trademark of Demeetra. VectorBuilder holds a license to sell products and provide custom services incorporating piggyBac® hyPBase for research purposes. Academic and non-profit researchers using it for research purposes are not required to obtain a separate license; commercial customers need a separate license from Demeetra.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

China-based AAV and lentiviral vector CDMO recognized alongside VectorBuilder as a key player in the global viral capsid development market. Directly comparable in service portfolio (vector cloning, virus packaging, GMP manufacturing) and customer mix (academic plus biotech).

TypeDirect peer
Description

Gene synthesis, plasmid preparation, viral vector, and cell therapy CRO/CDMO with overlapping capabilities in custom vector design and gene delivery services for academic and biotech customers globally.

TypeDirect peer
Description

China-rooted cell and gene therapy CRO offering custom vector construction, virus packaging, and animal model services. Comparable in serving academic and preclinical biotech customers with fee-for-service gene delivery.

TypeDirect peer
Description

DNA synthesis and gene services company with overlapping capabilities in synthetic genes, variant libraries, and antibody discovery, increasingly competing in gene delivery and gene therapy reagent workflows.

TypeBroad incumbent
Description

Global bioprocessing incumbent identified alongside VectorBuilder as a key player in the viral capsid development market, offering cell and gene therapy manufacturing solutions as part of a broader bioprocessing portfolio.

TypeBroad incumbent
Description

Life sciences tools and services company also named alongside VectorBuilder as a key player in viral capsid development, with broader portfolio across reagents, software, and gene therapy manufacturing services.

TypeBroad incumbent
Description

Large CDMO and preclinical CRO with cell and gene therapy manufacturing capabilities that compete with VectorBuilder's GMP viral vector and plasmid manufacturing services.

TypeBroad incumbent
Description

Global CDMO leader with one of the largest cell and gene therapy manufacturing footprints, competing head-to-head with VectorBuilder for GMP-grade viral vector and engineered cell therapy contracts.

TypeDirect peer
Description

Non-profit plasmid repository and viral vector service provider widely used by academic researchers; overlaps with VectorBuilder's research-grade plasmid and viral vector distribution in the academic customer segment.

TypeBroad incumbent
Description

Diversified life sciences platform with gene synthesis, viral vector production, and GMP cell therapy services through its Biosciences and Pharma Services segments, competing across multiple of VectorBuilder's service lines.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers14 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration7 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

VectorBuilder

Gene Delivery CDMO and Custom Vector Servicesvectorbuilder.com

VectorBuilder is a privately held gene-delivery CRO and CDMO operating an integrated online design platform (Vector Design Studio, used in 300,000+ labs) and global manufacturing footprint spanning research-grade cloning and virus packaging through GMP plasmid, viral vector, IVT RNA, LNP, and engineered cell production for academic, biotech, and pharmaceutical customers.

What VectorBuilder does

VectorBuilder is a privately held gene-delivery contract research, development, and manufacturing organization (CRO/CDMO) that operates an integrated online platform and physical manufacturing footprint to serve academic researchers, biotech, and pharmaceutical customers from research through GMP clinical manufacturing. The company's core technology is the Vector Design Studio — a self-serve web platform used in over 300,000 laboratories globally — paired with the free VectorBee DNA design software, an extensive catalog of backbones and components, and instant quote/pricing functionality. Revenue is generated through five streams: fee-for-service custom gene delivery (cloning, virus packaging, plasmid preparation, library construction, stable cell line engineering, recombinant protein expression), product sales (premade viruses, AAV serotype testing panels, LentiBuilder packaging kits, popular vectors), full-service CDMO/GMP manufacturing (plasmid, viral vector, IVT RNA, LNP, and engineered cell products) plus the CliniVec clinical consultation service, a store-credit program offering up to 20% bonus credit for pre-payment, and licensing/royalty arrangements (inbound from TET Systems and Demeetra/PiggyBac, plus outbound from proprietary platforms such as MiniVec, MuteFree AAV, MegaAAV, and novel AAV capsids). Go-to-market combines product-led growth through the self-serve online store, inside sales via territory managers, enterprise field sales for CDMO and CliniVec engagements, and a multi-region distributor network across Europe, the Middle East, and Asia Pacific.

The company is structured around US parent VectorBuilder Inc. (headquartered in Chicago, Illinois), core operating entity VectorBuilder Biotechnology in Guangzhou, China, regional entities in Germany (VectorBuilder GmbH) and the United Kingdom (VectorBuilder Ltd.), and local presences in Japan and Korea. In October 2022 VectorBuilder Biotechnology closed a CNY 410 million Series C funding round co-led by Legend Capital and Suikai Investment (with Guangzhou Yuexiu Industrial Investment Fund, Guangzhou Industrial Investment Group, Wanlian Tianze, and Xiamen C&D) to fund technology upgrades, capacity expansion, and global business development. Subsequent strategic actions include a $50M Chicago Advanced Biomanufacturing and R&D Center (announced May 2026, operations expected 2027), an EU patent for the proprietary MiniVec plasmid system (May 2026), the launch of the MuteFree AAV backbone (April 2026), a strategic partnership with MaxCyte for ex vivo cell engineering (June 2026), and a collaboration with Ikarovec on the ophthalmology gene therapy IKAR-003 (January 2026, potential $1B+ deal value). The company won the BioIndustrial Innovation of the Year award in 2024 and is recognized as a key player in the viral capsid development market alongside PackGene Biotech, Sartorius AG, and Revvity.

VectorBuilder firmographics

Firmographics
Name
VectorBuilder
Legal name
VectorBuilder Inc.
Website
https://vectorbuilder.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
101–250 employees
Short description
VectorBuilder is a privately held gene-delivery CRO and CDMO operating an integrated online design platform (Vector Design Studio, used in 300,000+ labs) and global manufacturing footprint spanning research-grade cloning and virus packaging through GMP plasmid, viral vector, IVT RNA, LNP, and engineered cell production for academic, biotech, and pharmaceutical customers.
Ownership category
akta.pro rank

VectorBuilder industry classification

Industry
Product category
Gene Delivery CDMO and Custom Vector Services
akta.pro industry
PRIMARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAB
Lentiviral Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAKAD
Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Custom vector cloning
  • Virus packaging services
  • CDMO gene therapy
  • GMP plasmid manufacturing
  • AAV lentivirus production

Where VectorBuilder is headquartered

Location

Headquarters

HQ city
Chicago
HQ country
United States
HQ region
North America

Offices7 records

Markets served

VectorBuilder business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Infrastructure, Technology or R&D, Marketing or Sales, Operations, Supply Chain

Revenue model

  1. Custom Gene Delivery Services (Fee-for-Service): Contract manufacturing / fee-for-service revenue for custom vector cloning, virus packaging, plasmid preparation, library construction, stable cell line engineering, and recombinant protein expression. Default payment terms Net30.
  2. Product Sales (Premade Vectors, Viruses, Kits): Catalog sales of premade viruses, AAV serotype testing panels, LentiBuilder packaging kits, popular vectors, and consumables ordered directly through the online store.
  3. CDMO / GMP Manufacturing: Full-service CDMO providing GMP-grade plasmid manufacturing, viral vector manufacturing, IVT RNA and LNP manufacturing, plus CliniVec therapeutic consultation services to clinical-stage cell and gene therapy developers.
  4. Store Credit & Promotional Pre-Paid Credits: Non-refundable store credit program offering up to 20% bonus credit for future purchases, providing cash-flow positive pre-payment and lock-in.
  5. Licensing & Royalty Arrangements: Licensing revenue from outbound licenses (PiggyBac from Demeetra, Tet3G from TET Systems) and inbound IP licensing arrangements for proprietary vector systems such as MiniVec, MuteFree AAV, novel AAV capsids, codon-optimized gene sequences, and proprietary virus packaging plasmids.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goCustom quote-based pricing for vector cloning, virus packaging, and CDMO services
FreemiumPay-as-you-goFree first vector promotion (up to $500 off)
OtherPay-as-you-go12th Anniversary Welcome Offer (20% / 15% / 10% off tiers)
OtherPay-as-you-goReferral Program (20%-off for new referee, 30%-off reward for referrer)
SubscriptionPay-as-you-goStore Credit purchase (up to 20% bonus)

Go-to-market motion6 records

Distribution channels4 records

Marketing channels9 records

VectorBuilder product offering

Product offering

Core offering

VectorBuilder is an online platform and contract manufacturer that designs, engineers, and produces custom gene delivery tools including vectors, viruses, plasmids, recombinant proteins, stable cell lines, and GMP-grade cell-and-gene-therapy materials. Its integrated Vector Design Studio lets researchers design and order custom vectors online, while its CDMO arm delivers GMP plasmid, viral vector, IVT RNA, LNP, and engineered cell manufacturing supported by proprietary platforms such as MiniVec, MuteFree AAV, MegaAAV, and LentiBuilder.

Differentiator

Problem solved

Functional benefit

Brands

  • VectorBee: Free DNA editing and design software offered as a companion to the VectorBuilder platform (vectorbee.com).
  • Vector Design Studio
  • CliniVec™
  • MiniVec™
  • MuteFree™
  • MegaAAV™
  • LentiBuilder™

Products and services

  • Online Vector Design (Vector Design Studio)

Companies that use VectorBuilder

Customer profile

Named customers14 records

Segments4 records

Ideal customer profiles3 records

VectorBuilder technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration7 records

Feature9 records

VectorBuilder partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered flagship, core, regional and minor.

  • MaxCyteflagshipStrategic or Co-development Partner · 23 June 2026Strategic partnership to co-develop a next-generation gene delivery solution combining VectorBuilder's MiniVec plasmid system with MaxCyte's Flow Electroporation technology for ex vivo cell engineering applications. Preliminary CAR-T manufacturing data demonstrated 2.4x increased cell viability and 1.4x higher gene expression compared to conventional systems, addressing critical challenges in safety and manufacturability for cell therapies.
  • IkaroveccoreStrategic or Co-development Partner · 6 January 2026Collaborating on an eye disease gene therapy, IKAR-003, designed to be delivered in a doctor's office. The partnership is still in early stages but could be valued at over $1 billion once finalized.
  • BiozolregionalChannel Partner/ Reseller/ DistributorAuthorized distributor covering Germany, Switzerland, and Austria markets, listed on the VectorBuilder distributors page.
  • DBA Compare (dbacompare.it)regionalChannel Partner/ Reseller/ DistributorAuthorized distributor for the Italian market, listed on the VectorBuilder distributors page.
  • AmplikonregionalChannel Partner/ Reseller/ DistributorAuthorized distributor covering the Hungarian market, listed on the VectorBuilder distributors page.
  • BiotagregionalChannel Partner/ Reseller/ DistributorAuthorized distributor covering the Israeli market, listed on the VectorBuilder distributors page.
  • Sci-Hub (sci-hub.com)regionalChannel Partner/ Reseller/ DistributorAuthorized distributor covering Malaysia, Singapore, and Indonesia, listed on the VectorBuilder distributors page.
  • GBBioregionalChannel Partner/ Reseller/ DistributorAuthorized distributor covering the Korean market, listed on the VectorBuilder distributors page; VectorBuilder also maintains its own Korean-language website (vectorbuilder.kr) with additional distributors.
  • TET SystemsminorOEM/ Whitelabel/ Licensing PartnerLicensor of the patented Tet3G sequence component used in VectorBuilder's Tet-inducible vector products. VectorBuilder holds an inbound license and grants automatic research-use licenses to academic institutions with purchase; commercial users require a separate TET Systems license.
  • Demeetra (PiggyBac)minorOEM/ Whitelabel/ Licensing PartnerPiggyBac® is a licensed trademark of Demeetra. VectorBuilder holds a license to sell products and provide custom services incorporating piggyBac® hyPBase for research purposes. Academic and non-profit researchers using it for research purposes are not required to obtain a separate license; commercial customers need a separate license from Demeetra.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

VectorBuilder competitors and assessment

Company assessment

Direct peers

  • PackGene Biotech: China-based AAV and lentiviral vector CDMO recognized alongside VectorBuilder as a key player in the global viral capsid development market. Directly comparable in service portfolio (vector cloning, virus packaging, GMP manufacturing) and customer mix (academic plus biotech).
  • GenScript: Gene synthesis, plasmid preparation, viral vector, and cell therapy CRO/CDMO with overlapping capabilities in custom vector design and gene delivery services for academic and biotech customers globally.
  • Cyagen Biosciences: China-rooted cell and gene therapy CRO offering custom vector construction, virus packaging, and animal model services. Comparable in serving academic and preclinical biotech customers with fee-for-service gene delivery.
  • Twist Bioscience: DNA synthesis and gene services company with overlapping capabilities in synthetic genes, variant libraries, and antibody discovery, increasingly competing in gene delivery and gene therapy reagent workflows.
  • Addgene: Non-profit plasmid repository and viral vector service provider widely used by academic researchers; overlaps with VectorBuilder's research-grade plasmid and viral vector distribution in the academic customer segment.

Broad incumbents

  • Sartorius AG: Global bioprocessing incumbent identified alongside VectorBuilder as a key player in the viral capsid development market, offering cell and gene therapy manufacturing solutions as part of a broader bioprocessing portfolio.
  • Revvity: Life sciences tools and services company also named alongside VectorBuilder as a key player in viral capsid development, with broader portfolio across reagents, software, and gene therapy manufacturing services.
  • Charles River Laboratories: Large CDMO and preclinical CRO with cell and gene therapy manufacturing capabilities that compete with VectorBuilder's GMP viral vector and plasmid manufacturing services.
  • Lonza Group: Global CDMO leader with one of the largest cell and gene therapy manufacturing footprints, competing head-to-head with VectorBuilder for GMP-grade viral vector and engineered cell therapy contracts.
  • Thermo Fisher Scientific: Diversified life sciences platform with gene synthesis, viral vector production, and GMP cell therapy services through its Biosciences and Pharma Services segments, competing across multiple of VectorBuilder's service lines.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

VectorBuilder social profiles

Digital presence

VectorBuilder financial estimates

Financial estimate

Revenue estimate

Valuation estimate

VectorBuilder leadership team

Management profile

Number of profiles

Profiles3 records

VectorBuilder subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

VectorBuilder funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

VectorBuilder M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VectorBuilder

What does VectorBuilder do?

VectorBuilder is an online platform and contract manufacturer that designs, engineers, and produces custom gene delivery tools including vectors, viruses, plasmids, recombinant proteins, stable cell lines, and GMP-grade cell-and-gene-therapy materials. Its integrated Vector Design Studio lets researchers design and order custom vectors online, while its CDMO arm delivers GMP plasmid, viral vector, IVT RNA, LNP, and engineered cell manufacturing supported by proprietary platforms such as MiniVec, MuteFree AAV, MegaAAV, and LentiBuilder.

Is VectorBuilder a public or private company?

VectorBuilder is a private company. It is classified as venture growth investor backed and is currently operating.

When was VectorBuilder founded?

VectorBuilder was founded in 2014. It employs 101 to 250 people.

Where is VectorBuilder based?

VectorBuilder is headquartered in Chicago, United States, in the North America region.

How does VectorBuilder make money?

Five revenue lines are on record. Custom Gene Delivery Services (Fee-for-Service) is the primary driver. The others are product Sales (Premade Vectors, Viruses, Kits), CDMO / GMP Manufacturing, store Credit & Promotional Pre-Paid Credits and licensing & Royalty Arrangements.

Who are VectorBuilder's main competitors?

Direct peers on record are PackGene Biotech, GenScript, Cyagen Biosciences, Twist Bioscience and Addgene. Broad incumbents are Sartorius AG, Revvity, Charles River Laboratories, Lonza Group and Thermo Fisher Scientific.

Does VectorBuilder have an API?

No public API is recorded for VectorBuilder.

What industry is VectorBuilder in?

VectorBuilder's product category is Gene Delivery CDMO and Custom Vector Services. Its primary akta.pro industry code is HLAAACAJ, Gene Therapy Vector Manufacturing & CDMO Services, with a secondary code of HLAAACAA, AAV Vector Gene Therapy Developers.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire Blog2026 BioTech Breakthrough Honors VectorBuilder With “Overall CGT Solution Provider of the Year”VectorBuilder was named "Overall CGT Solution Provider of the Year" in the sixth annual BioTech Breakthrough Awards. The company integrates vector design, cloning, packaging, and GMP manufacturing, and its DeepCap platform uses machine learning to engineer AAV capsids. The award recognizes its integrated approach to gene delivery.Business Wire BlogVectorBuilder to Present at the ASHG 2026 Annual MeetingVectorBuilder will present and exhibit at the ASHG 2026 Annual Meeting in Montréal, Canada, October 20–24. Dr. Morgan Dwyer will present on developing a compact bidirectional promoter for coordinated multi-gene expression, and the company will occupy booth 1103.PrtimesAIで遺伝子治療の実用化を加速、VectorBuilderとLir Therapeuticsが次世代AAVカプシド開発で提携VectorBuilder and Lir Therapeutics announced a strategic partnership to develop next-generation AAV capsids for gene therapy. The collaboration combines VectorBuilder's capsid engineering and GMP manufacturing with Lir Therapeutics' AI platform nAAVigator, aiming to improve manufacturability and clinical translation. Both companies plan to continue AI-driven design and manufacturing evaluation for therapeutic areas.Business Wire BlogVectorBuilder and Lir Therapeutics Partner to Advance AAV Capsids Designed for Clinical SuccessVectorBuilder and Lir Therapeutics announced a strategic collaboration to jointly develop adeno-associated virus (AAV) capsids that combine strong biological performance with manufacturability for clinical gene therapies. The partnership integrates VectorBuilder’s GMP manufacturing and capsid engineering expertise with Lir Therapeutics’ proprietary nAAVigator® AI platform to optimize existing high-potential vectors. This initiative aims to address critical industry bottlenecks by enhancing yield, process robustness, and tissue specificity from the early stages of development.Business Wire BlogVectorBuilder Advances Free VectorBee Software to Help Researchers Work with Greater Control and FlexibilityVectorBuilder has released a major update to VectorBee, its free DNA sequence viewing, editing, annotation, and analysis software, adding new features including a Vector Design Wizard for greater control and flexibility in genetic engineering workflows. The software has attracted hundreds of thousands of users since its 2024 launch and now offers deeper integration with VectorBuilder's cloning and downstream services, allowing researchers to seamlessly transition from design to custom vector orders. The update reflects VectorBuilder's ongoing commitment to providing free researcher-focused tools under its Good Vector Practice framework.RegmednetCell therapy weekly: nanoparticle platform for targeted gene therapyThree cell and gene therapy developments were reported this week: Syntax Bio expanded its Series A funding round to $14.4 million (total capital raised exceeding $25 million) to advance its Cellgorithm™ CRISPR-based platform and a beta cell therapy for type 1 diabetes; VectorBuilder and MaxCyte formed a strategic partnership combining VectorBuilder's MiniVec plasmid platform with MaxCyte's Flow Electroporation® technology for ex vivo cell engineering, demonstrating a 2.4-fold improvement in cell viability and 1.4-fold improvement in gene expression in CAR-T manufacturing; and Hatch BioFund invested in Optimeos Life Sciences, a Princeton University spinout whose proprietary nanoparticle platform (CINCs) achieves over 90% encapsulation efficiency for delivering therapeutic macromolecules including gene therapies targeting rare diseases and T cell engineering.BioSpaceVectorBuilder Partners With MaxCyte® to Advance Clinical-Grade Cell EngineeringVectorBuilder and MaxCyte announced a partnership to co-develop a gene delivery solution combining VectorBuilder's MiniVec plasmid system with MaxCyte's Flow Electroporation platform for ex vivo cell engineering. Preliminary data showed 2.4x increased cell viability and 1.4x higher gene expression in CAR-T manufacturing. The platform aims to improve safety and scalability for cell therapies like CAR-T and CAR-NK.Business Wire BlogVectorBuilder Partners With MaxCyte® to Advance Clinical-Grade Cell EngineeringVectorBuilder and MaxCyte announced a strategic partnership to co-develop a next-generation gene delivery solution combining VectorBuilder's MiniVec plasmid system with MaxCyte's Flow Electroporation technology for ex vivo cell engineering applications. Preliminary CAR-T manufacturing data demonstrated 2.4x increased cell viability and 1.4x higher gene expression compared to conventional systems, addressing critical challenges in safety and manufacturability for cell therapies. The companies stated the combined platform aims to provide a more streamlined path from research through commercialization for developers of cell-based therapies.GenengnewsNextgen Platform Combines VectorBuilder and Maxcyte Technologies to Boost Clinical-Grade Cell EngineeringVectorBuilder and MaxCyte announced a partnership to co-develop a gene delivery solution combining VectorBuilder's MiniVec plasmid system and MaxCyte's electroporation platform. The platform aims to improve cell viability and transfection efficiency for ex vivo therapies like CAR-T, addressing safety and manufacturability challenges.